Saturday 17 October 2026
Export CNSP’s income statement to Excel — free account
CNS Pharmaceuticals, Inc.
CNSP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.1% and free cash flow grew 33.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.33
−6.37%
Follow CNSP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (106.62%) | (298.64%) | (296.28%) | (197.12%) |
+8 more TTM periods Free account |
|
| (91.64%) | (179.17%) | (182.99%) | (135.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (17,934.92%) | |
Return on Tangible Assets |
(91.75%) | 3,418.98% | (394.29%) | (138.53%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.97) | (22.56) | (31.24) | (29.03) | |
Free Cash Flow |
(13.45) | (15.25) | (13.84) | (16.23) | |
Capital Expenditures |
(0.03) | (0.03) | (0.03) | — | |
| Other line items | |||||
Cash ROIC |
(35.21%) | (504.65%) | (118.03%) | (82.08%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,120.21) | (1,100.93) | (1,051.75) | (874.18) | |
Operating CF/Net income |
0.80 | 0.92 | 0.87 | 1.24 | |
Depreciation/Fixed assets |
0.99 | 0.21 | 0.22 | 1.26 | |
Capex/Depreciation |
(2.17) | (6.55) | (6.74) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.96) | (22.51) | (31.18) | (29.03) | |
Capex per Share |
0.00 | (0.05) | (0.06) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates